biostudies-literatureGristina VPiano Nazionale di Ripresa e Resilienza (PNRR) project - Italian Network of excellence for advanced diagnosis (INNOVA)1422-1435https://www.ebi.ac.uk/biostudies/studies/S-EPMC12077285biostudies-literatureUnknown19(5)Extracellular vesicle (EV) monitoring can complement clinical assessment of cancer response. In this study, patients with advanced non-small cell lung cancer (NSCLC) undergoing osimertinib, alectinib, pembrolizumab or platinum-based chemotherapy ± pembrolizumab were enrolled. EVs were characterized using Bradford assay to quantify the circulating cell-free EV protein content (cfEV), and dynamic light scattering to assess Rayleigh ratio excess at 90°, z-averaged hydrodynamic diameter and polydispersity index. A total of 135 plasma samples from 27 patients were collected at baseline (T0) and at the first radiological restaging (T1). A ∆cfEV < 20% was associated with improved median progression-free survival (mPFS) in responders versus non-responders. Specifically, cfEV responders on pembroliMolecular oncologyOn-treatment dynamics of circulating extracellular vesicles in the first-line setting of patients with advanced non-small cell lung cancer: the LEXOVE prospective study.PMC12077285PNC-E3-2022-23683266 PNC-HLS-DA (C43C22001630001)Bazan Russo TDTaverna SCarreca APTroncone GSantini DGalvano AManno MBono MRaccosta SBarraco NPepe FBadalamenti GBazan VIncorvaia LMalapelle UPisapia PRusso AGristina VfalseOn-treatment dynamics of circulating extracellular vesicles in the first-line setting of patients with advanced non-small cell lung cancer: the LEXOVE prospective study.Extracellular vesicle (EV) monitoring can complement clinical assessment of cancer response. In this study, patients with advanced non-small cell lung cancer (NSCLC) undergoing osimertinib, alectinib, pembrolizumab or platinum-based chemotherapy ± pembrolizumab were enrolled. EVs were characterized using Bradford assay to quantify the circulating cell-free EV protein content (cfEV), and dynamic light scattering to assess Rayleigh ratio excess at 90°, z-averaged hydrodynamic diameter and polydispersity index. A total of 135 plasma samples from 27 patients were collected at baseline (T0) and at the first radiological restaging (T1). A ∆cfEV < 20% was associated with improved median progression-free survival (mPFS) in responders versus non-responders. Specifically, cfEV responders on pembroli2025-01-01T00:00:00Z2025 May2026-07-15T08:30:02.995Z2026-07-01T03:11:58.785ZS-EPMC120772853978074910.1002/1878-0261.13737